Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

VYNE Therapeutics Q3 EPS $(0.17) Misses $(0.13) Estimate, Sales $169.000K Beat $100.000K Estimate

Author: Benzinga Newsdesk | November 06, 2025 08:29am
VYNE Therapeutics (NASDAQ:VYNE) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.13) by 30.77 percent. This is a 41.38 percent increase over losses of $(0.29) per share from the same period last year. The company reported quarterly sales of $169.000 thousand which beat the analyst consensus estimate of $100.000 thousand by 69.00 percent. This is a 39.67 percent increase over sales of $121.000 thousand the same period last year.

Posted In: VYNE


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist